Loading…
OmniAb, Inc. is projected to rise to $2.11 by 2027, a +7% move from its current price of $1.98. OABI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.93 | $1.98 | $2.04 | +0.05% |
| Aug 4 | $1.91 | $1.98 | $2.06 | +0.09% |
| Aug 5 | $1.89 | $1.98 | $2.08 | +0.14% |
| Aug 6 | $1.88 | $1.98 | $2.10 | +0.19% |
| Aug 7 | $1.87 | $1.98 | $2.11 | +0.23% |
| Aug 8 | $1.86 | $1.99 | $2.12 | +0.28% |
| Aug 9 | $1.85 | $1.99 | $2.14 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.85 | $1.99 | $2.14 | +0.33% |
| Week 2 | $1.80 | $1.99 | $2.21 | +0.65% |
| Week 3 | $1.76 | $2.00 | $2.27 | +0.98% |
| Week 4 | $1.73 | $2.01 | $2.32 | +1.31% |
| Week 5 | $1.71 | $2.01 | $2.37 | +1.64% |
| Week 6 | $1.69 | $2.02 | $2.41 | +1.97% |
| Week 7 | $1.67 | $2.03 | $2.45 | +2.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The OmniAb platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Its Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.
It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
OmniAb, Inc. (OABI) is currently trading at $2.08 per share. Its market capitalization stands at $301.54M, and it ranks 3513 by market cap.
The price outlook from the year-by-year forecast points to a bullish trajectory over the longer term, with the average price rising from $2.08 in 2026 toward higher levels by 2030 and beyond. The forecast includes a broad range of potential outcomes, with max values extending into the high single digits and beyond by 2050, reflecting meaningful upside potential alongside elevated risk.
A major floor 31.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 29.8% above — a clean break opens room to run.
A major ceiling 40.7% above — clearing it would confirm fresh momentum.
Key OABI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OABI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.98 | Sell | $1.99 | Sell |
| MA 10 | $2.03 | Sell | $2.03 | Sell |
| MA 20 | $2.12 | Sell | $2.10 | Sell |
| MA 50 | $2.31 | Sell | $2.14 | Sell |
| MA 100 | $1.98 | Sell | $2.06 | Sell |
| MA 200 | $1.88 | Buy | $2.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.34 | Neutral |
| Stoch RSI (14) | 37.69 | Neutral |
| CCI (20) | -89.95 | Neutral |
| Williams %R (14) | -84.21 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -4.81 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 15.79 | Buy |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 26.86 | Buy |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 1.95 | Buy |
| ADX (14) | 19.12 | Neutral |
| ATR (14) | 0.05 | Info |
30-day picture shows neutral sentiment with RSI14 at 40. SMA50 is $2.26 and SMA200 is $1.86, indicating near-term convergence around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.98 | $2.53 | 0% | Neutral | |
| $1.68 | $2.11 | $2.80 | +7% | Neutral | |
| $2.03 | $2.63 | $3.62 | +33% | Bullish | |
| $2.42 | $3.19 | $4.53 | +61% | Bullish | |
| $2.44 | $3.29 | $4.78 | +66% | Bullish | |
| $2.55 | $3.50 | $5.21 | +77% | Bullish | |
| $2.54 | $3.55 | $5.38 | +79% | Bullish | |
| $2.60 | $3.70 | $5.70 | +87% | Bullish | |
| $3.12 | $4.50 | $7.05 | +127% | Bullish | |
| $3.39 | $4.97 | $7.90 | +151% | Bullish | |
| $4.25 | $6.66 | $11.27 | +236% | Bullish | |
| $7.62 | $13.43 | $24.86 | +578% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.36 | $1.98 | $2.38 | +0.00% |
| September 2026 | $1.68 | $1.99 | $2.42 | +0.39% |
| October 2026 | $1.73 | $2.07 | $2.54 | +3.93% |
| November 2026 | $1.75 | $2.09 | $2.59 | +1.25% |
| December 2026 | $1.68 | $2.02 | $2.53 | -3.41% |
Click any year to see its month-by-month OABI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OABI is projected to trade between $1.36 and $2.53, averaging $1.98 — a potential gain of 0% from today's $1.98. Price action looks broadly range-bound.
OmniAb, Inc.'s 2027 outlook centres on $2.11, within a $1.68 to $2.80 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, OABI could reach as high as $3.62, with a base case around $2.63 and support toward $2.03 — roughly +33% from $1.98. Momentum favours further upside here.
Expect OABI to range from $2.42 to $4.53 through 2029. The $3.19 average target implies a +61% move from current prices. That is up +22% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The OABI price prediction for 2030 points to an average of $3.29 (low $2.44, high $4.78) — a potential gain of +66% on today's $1.98. Momentum favours further upside here.
In 2031, OABI is projected to trade between $2.55 and $5.21, averaging $3.50 — a potential gain of +77% from today's $1.98. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
OmniAb, Inc.'s 2032 outlook centres on $3.55, within a $2.54 to $5.38 range. That is up +1% on the projected 2031 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2033, OABI could reach as high as $5.70, with a base case around $3.70 and support toward $2.60 — roughly +87% from $1.98. Buyers look set to stay in control over this stretch.
Expect OABI to range from $3.12 to $7.05 through 2034. The $4.50 average target implies a +127% move from current prices. That is up +22% on the projected 2033 average. Momentum favours further upside here.
The OABI price prediction for 2035 points to an average of $4.97 (low $3.39, high $7.90) — a potential gain of +151% on today's $1.98. Buyers look set to stay in control over this stretch.
In 2040, OABI is projected to trade between $4.25 and $11.27, averaging $6.66 — a potential gain of +236% from today's $1.98. That is up +34% on the projected 2035 average. Momentum favours further upside here.
OmniAb, Inc.'s 2050 outlook centres on $13.43, within a $7.62 to $24.86 range. That is up +102% on the projected 2040 average. That marks a +578% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in OABI today (≈ 505.050505 OABI) could be worth
$6,780.33
+$5,780.33 (+578%) by 2050 · US Dollar
Based on the average projected OABI price of $13.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OABIwould be worth at today's price.
$1,000 invested in OABI on Jul 31, 2025 (≈ 523.560219 OABI) would be worth
$1,036.65
+$36.65 (+3.7%) today · 1.04× · US Dollar
Based on a OABI entry price of $1.91 vs. today's $1.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.03 | $975.37 | -2.5% |
| 1 month ago | $2.39 | $828.45 | -17.2% |
| 3 months ago | $1.4 | $1,414.29 | +41.4% |
| 6 months ago | $1.79 | $1,106.15 | +10.6% |
| 1 year ago | $1.91 | $1,036.65 | +3.7% |
| All time (4.8y) ago | $9.76 | $202.87 | -79.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OABI forecast.
Our base-case forecast reaches $4.00 around 2034.
Implied market cap at $4.00: $579.89M
The multi-year forecast shows a bullish trajectory across the horizon. In 2026, the avg is $2.08 with ROI 0 and sentiment NEUTRAL. By 2027, avg rises to $2.21 with ROI 6.1 and NEUTRAL sentiment.
The forecast accelerates into 2028 with avg $2.73 and ROI 31.1, then into 2029 with avg $3.42 and ROI 64.4. By 2030, avg is $3.51 with ROI 68.8 and BULLISH sentiment. Outlook continues to strengthen through 2031 ($3.55, ROI 70.8), 2032 ($3.62, ROI 73.8), and 2033 ($3.77, ROI 81.3).
Mid-horizon growth remains pronounced: 2034 avg $4.52 (ROI 117.1), 2035 avg $5.14 (ROI 147). The long-range view shows substantial upside, with 2040 avg $6.64 (ROI 219.2) and 2050 avg $13.37 (ROI 542.9). The max values rise to $27.69 in 2050, with a bullish sentiment prevailing.
Note that these are estimates and not guarantees, and volatility is indicated by the 70% annualized volatility.
Tap a question to reveal the answer.
In 2030 the forecasted average price is $3.51 with a min of $2.46 and a max of $5.44; ROI is 68.8 and sentiment is BULLISH.
Forecasts show rising averages from $2.08 in 2026 to $13.37 in 2050, with ROI reaching 542.9% in 2050 and a shifting bullish sentiment from 2028 onward, though these are estimates and not guarantees.
Yes. The 2030 max is forecast at $5.44, with higher maxima in later years (e.g., 2034 max $7.66, 2035 max $8.87, 2040 max $12.35, 2050 max $27.69).
Current price is $2.08 and market cap is $301.54M.
RSI14 is 40 (NEUTRAL). The SMA50 is $2.26 and the SMA200 is $1.86. Support is $2.02 and resistance is $2.66, with a 30-day range of $1.64 to $2.64.
OmniAb, Inc. Community Discussion
0Share your OmniAb, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.